Institute of Cardiovascular and Medical Sciences

Dr George Baillie

  • Reader (Institute of Cardiovascular and Medical Sciences)

telephone: 1662
email: George.Baillie@glasgow.ac.uk


George graduated from Glasgow University in 1988 with an upper second class Honours degree in Agricultural Botany before undertaking a PhD in pharmacology at the University of Kent in conjunction with Pfizer, investigating the mechanisms of action of a novel antifungal compound. Following graduation in 1993, Dr Baillie moved back to Glasgow to Strathclyde University to undertake his first post-doctoral position with Dr Gavin Halbert at the MRC formulation unit to study new lipid based drug delivery systems. Dr Baillie then transferred back to Glasgow University to the laboratory of Dr L. Julia Douglas to focus on novel therapies for the eradication of recalcitrant Candida Albicans infections. Following a chance meeting with Professor Miles Houslay , George agreed to move to the Gardiner Laboratory and became the permanent laboratory manager for a period of 10 years in which time he published over 30 papers on many aspects of the cAMP signaling pathway in disease. Dr Baillie was appointed as a lecturer in 2007 and initiated independent research programmes investigating factors that underpin spatial and temporal cAMP signaling. His major discovery was that phosphodiesterases (enzymes that degrade cAMP) are “compartmentalized”, and it is their location within cells that direct their function. The Baillie lab was the first to discover a specific function for a single isoform of PDE4 (namely PDE4D5 with beta-arrestin desensitizes the beta2-adrenergic receptor) and this was published in Science. His lab has since gone on to ascribe functions to several other PDE4 isoforms and these discoveries have been published in Science, Nature, PNAS, EMBO, Molecular Cell and Current Biology. Dr Baillie was promoted to Reader in 2011. Over the years the Baillie lab has amassed a huge number of biological tools to facilitate research into the function of PDEs and combined with his broad knowledge of and expertise in PDE research, Dr Baillie is uniquely placed within the cAMP signaling field. His current areas of focus are translational and include:

Development of a new class of Phosphdiesterase inhibitors
As targeting and compartmentalization are fundamental to the functioning of PDE4s, current small molecule PDE4 inhibitors generate unpleasant side effects as a result of the universal inhibition of all isoforms. Recently proposed dominant negative and siRNA approaches are also limited by the fact that they are not directed against discretely localized sub-pools of individual PDE4 isoforms. In this regard, future PDE4 isoform-selective inhibitors should be aimed at the cellular targeting of the enzymes rather than their catalytic activity. One such approach has been facilitated by the introduction of a technique pioneered by the Baillie laboratory called peptide array technology. This technique allows rapid determination of the molecular nature of PDE derived protein-protein interactions by using the sequence of one of the interacting partners to generate a library of spotted, immobilized peptides that is probed by a purified, recombinant form of the other protein partner using a simple “far-western” overlay protocol. Positive spots contain putative binding sequences that can then be used to inform mutagenesis studies to map interaction sites in cellular proteins. This approach has been used extensively by the Baillie lab in the cAMP signaling field to map interactions between PDE4 enzymes and the signaling proteins HSP20, DISC1, beta-arrestin, RACK, EPAC, Ndel and the SUMO E3 ligase PIASy. The identified sequences can also be transferred into powerful small peptide agents that have the potential to interfere with PDE4 protein interactions in vivo and help link targets with phenotypes. The beta-arrestin-PDE4D5 disruptor, for example, attenuated recruitment of PDE4D5 the beta2-adrenergic receptor leading to a hyper-phosphorylation of the receptor after stimulation whereas the RACK1-PDE4D5 disruptor was effective in preventing the formation of spreading initiation centers in cancer cells. Clearly, both peptides have potential as therapeutics, the former for the treatment of asthma where PDE4D5 is upregulated following chronic bronchodilator use and is a key regulator of beta2-Ar induced cAMP turnover within human smooth muscle, the latter as an agent to prevent polarization and metastasis of cancer cells.

Inhibition of the Ubiquitin/Proteosome System (UPS inhibitors)
Protein degradation by the proteosome and lysosome is a dynamic process that has been shown to be crucial for cellular homeostasis. Indeed, understanding how proteins are degraded can provide important insights into the process of many diseases. The Baillie lab is a world leader in using peptide array to map sites of protein-protein interaction. The laboratory has two state of the art peptide array robots that can synthesise immobilized peptide libraries for use in studies that seek to fine map sites of association between two proteins of interest. We have a tried and tested assay workflow that allows us to take the information gleaned from the peptide array analysis to develop high affinity peptide disruptors of ubiquitin E3 ligases. We are currently developing two different E3 ligase inhibitors for the treatment of Prostate cancer and Scizophrenia.

Member:

Heart Research Theme

Jump to: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
Number of items: 92.

2013

Cameron, R.T., Coleman, R.G., Day, J.P., Yalla, K.C., Houslay, M.D., Adams, D.R., Shoichet, B.K., and Baillie, G.S. (2013) Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochemical Pharmacology, 85 (9). pp. 1297-1305. ISSN 0006-2952 (doi:10.1016/j.bcp.2013.02.026)

Berthouze-Duquesnes, M., Lucas, A., Saulière, A., Sin, Y.Y., Laurent, A.C., Galés, C., Baillie, G., and Lezoualc'h, F. (2013) Specific interactions between Epac1, β-arrestin2 and PDE4D5 regulate β-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling. Cellular Signalling, 25 (4). pp. 970-980. ISSN 0898-6568 (doi:10.1016/j.cellsig.2012.12.007)

Murcia, P.R. et al. (2013) Evolution of equine influenza virus in vaccinated horses. Journal of Virology, 87 (8). pp. 4768-4771. ISSN 0022-538X (doi:10.1128/JVI.03379-12)

Lee, L.C.Y., Maurice, D.H., and Baillie, G.S. (2013) Targeting protein–protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Medicinal Chemistry, 5 (4). pp. 451-464. ISSN 1756-8919 (doi:10.4155/fmc.12.216)

Brown, K.M. et al. (2013) Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proceedings of the National Academy of Sciences of the United States of America . ISSN 0027-8424 (doi:10.1073/pnas.1303004110) (In Press)

Zarros, A., Kalopita, K., Tsakiris, S., and Baillie, G.S. (2013) Can acetylcholinesterase activity be considered as a reliable biomarker for the assessment of cadmium-induced neurotoxicity? Food and Chemical Toxicology . ISSN 0278-6915 (doi:10.1016/j.fct.2013.02.048) (In Press)

2012

Havekes, R. et al. (2012) Gravin orchestrates protein kinase A and 2-adrenergic receptor signaling critical for synaptic plasticity and memory. Journal of Neuroscience, 32 (50). pp. 18137-18149. ISSN 0270-6474 (doi:10.1523/JNEUROSCI.3612-12.2012)

Brown, K.M., Lee, L.C.Y., Findlay, J.E., Day, J.P., and Baillie, G.S. (2012) Cyclic AMP-specific phosphodiesterase, PDE8A1, is activated by protein kinase A-mediated phosphorylation. Febs Letters, 586 (11). pp. 1631-1637. (doi:10.1016/j.febslet.2012.04.033)

Cameron, R.T., and Baillie, G.S. (2012) cAMP-specific phosphodiesterase: modulation, inhibition and activation. In: Botana, L.M. and Loza, M. (eds.) Therapeutic Targets: Modulation, Inhibition, and Activation. John Wiley & Sons Ltd, Hoboken, N.J.. ISBN 9780470587195

Edwards, H.V., Scott, J.D., and Baillie, G.S. (2012) The A-kinase-anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser16. Biochemical Journal, 446 (3). pp. 437-443. ISSN 0264-6021 (doi:10.1042/BJ20120570)

Edwards, H.V., Scott, J.D., and Baillie, G.S. (2012) PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects. Biochemical Society Transactions, 40 (1). pp. 210-214. ISSN 0300-5127 (doi:10.1042/BST20110673)

Sin, Y.Y., and Baillie, G.S. (2012) Protein kinase D in the hypertrophy pathway. Biochemical Society Transactions, 40 (1). pp. 287-289. ISSN 0300-5127 (doi:10.1042/BST20110626)

2011

Christian, F. et al. (2011) Small molecule AKAP/PKA interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. Journal of Biological Chemistry, 286 . pp. 9079-9096. ISSN 0021-9258 (doi:10.1074/jbc.M110.160614)

Christian, F. et al. (2011) Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. Journal of Biological Chemistry, 286 (11). pp. 9079-9096. ISSN 0021-9258 (doi:10.1074/jbc.M110.160614)

Anthony, D.F., Sin, Y.Y., Vadrevu, S., Advant, N., Day, J.P., Byrne, A.M., Lynch, M.J., Milligan, G., Houslay, M.D., and Baillie, G.S. (2011) β Arrestin 1 inhibits the GAP function of ARHGAP21 so as to promote the activation of RhoA following angiotensin II type 1A receptor stimulation. Molecular and Cellular Biology, 31 (5). pp. 1066-1075. ISSN 0270-7306 (doi:10.1128/MCB.00883-10)

Day, J.P. et al. (2011) Elucidation of a Structural Basis for the Inhibitor-Driven, p62 (SQSTM1)-Dependent Intracellular Redistribution of cAMP Phosphodiesterase-4A4 (PDE4A4). Journal of Medicinal Chemistry, 54 (9). pp. 3331-3347. ISSN 0022-2623 (doi:10.1021/jm200070e)

Edwards, H.V., Cameron, R.T., and Baillie, G.S. (2011) The emerging role of HSP20 as a multifunctional protective agent. Cellular Signalling, 23 (9). pp. 1447-1454. ISSN 0898-6568 (doi:10.1016/j.cellsig.2011.05.009)

Edwards, H.V., Christian, F., and Baillie, G.S. (2011) cAMP: Novel concepts in compartmentalised signalling. Seminars in Cell and Developmental Biology . ISSN 1084-9521 (doi:10.1016/j.semcdb.2011.09.005)

Kean, M. J. et al. (2011) Structure-Function Analysis of Core STRIPAK Proteins: A SIGNALING COMPLEX IMPLICATED IN GOLGI POLARIZATION. Journal of Biological Chemistry, 286 (28). pp. 25065-25075. ISSN 0021-9258 (doi:10.1074/jbc.M110.214486)

Lima-Fernandes, E. et al. (2011) Distinct functional outputs of PTEN signalling are controlled by dynamic association with β-arrestins. EMBO Journal, 30 (13). pp. 2557-2568. ISSN 0261-4189 (doi:10.1038/emboj.2011.178)

MacKenzie, K.F., Wallace, D.A., Hill, E.V., Anthony, D.F., Henderson, D.J.P., Houslay, D.M., Arthur, J.S.C., Baillie, G.S., and Houslay, M.D. (2011) Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochemical Journal, 435 (3). pp. 755-769. ISSN 0264-6021 (doi:10.1042/BJ20101184)

Reijns, M.A.M., Bubeck, D., Gibson, L.C.D., Graham, S.C., Baillie, G.S., Jones, E.Y., and Jackson, A.P. (2011) The Structure of the Human RNase H2 Complex Defines Key Interaction Interfaces Relevant to Enzyme Function and Human Disease. Journal of Biological Chemistry, 286 (12). pp. 10530-10539. ISSN 0021-9258 (doi:10.1074/jbc.M110.177394)

Sin, Y.Y., Edwards, H.V., Li, X., Day, J.P., Christian, F., Dunlop, A.J., Adams, D.R., Zaccolo, M., Houslay, M.D., and Baillie, G.S. (2011) Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)–HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes. Journal of Molecular and Cellular Cardiology, 50 (5). pp. 872-883. ISSN 0022-2828 (doi:10.1016/j.yjmcc.2011.02.006)

2010

Christian, F., Anthony, D.F., Vadrevu, S., Riddell, T., Day, J.P., McLeod, R., Adams, D.R., Baillie, G.S., and Houslay, M.D. (2010) p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cellular Signalling, 22 (10). pp. 1576-1596. ISSN 0898-6568 (doi:10.1016/j.cellsig.2010.06.003)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38 (4). pp. 1058-1061. ISSN 0300-5127 (doi:10.1042/BST0381058)

Serrels, B., Sandilands, E., Serrels, A., Baillie, G., Houslay, M.D., Brunton, V.G., Canel, M., Machesky, L.M., Anderson, K.I., and Frame, M.C. (2010) A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Current Biology, 20 (12). pp. 1086-1092. ISSN 0960-9822 (doi:10.1016/j.cub.2010.04.042)

Li, X. et al. (2010) Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochemical Journal, 428 (1). pp. 55-65. ISSN 0264-6021 (doi:10.1042/BJ20091672)

Bjorgo, E., Solheim, S.A., Abrahamsen, H., Baillie, G., Brown, K.M., Berge, T., Okkenhaug, K., Houslay, M.D., and Tasken, K. (2010) Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase A signaling pathways at the level of a protein kinase B/β-Arrestin/cAMP phosphodiesterase 4 complex. Molecular and Cellular Biology, 30 (7). pp. 1660-1672. ISSN 0270-7306 (doi:10.1128/MCB.00696-09)

Schafer, P.H. et al. (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. British Journal of Pharmacology, 159 (4). pp. 842-855. ISSN 0007-1188 (doi:10.1111/j.1476-5381.2009.00559.x)

Bird, R.J., Baillie, G.S., and Yarwood, S.J. (2010) Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C. Biochemical Journal, 432 (1). pp. 207-216. ISSN 0264-6021 (doi:10.1042/BJ20101010)

Burton, P. et al. (2010) Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 432 (3). pp. 575-584. ISSN 0264-6021 (doi:10.1042/BJ20100726)

Burton, Peter et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38 (4). pp. 1058-1061. ISSN 0300-5127 (doi:10.1042/BST0381058)

Rampersad, S. N., Ovens, J. D., Huston, E., Umana, M. B., Wilson, L. S., Netherton, S. J., Lynch, M. J., Baillie, G.S., Houslay, M.D., and Maurice, D. H. (2010) Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability. Journal of Biological Chemistry, 285 (44). pp. 33614-33622. ISSN 0021-9258 (doi:10.1074/jbc.M110.140004)

Xu, T. et al. (2010) Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Science Signaling, 3 (113). ra20. ISSN 1945-0877 (doi:10.1126/scisignal.2000517)

Zhu, H. et al. (2010) Evolutionarily Conserved Role of Calcineurin in Phosphodegron-Dependent Degradation of Phosphodiesterase 4D. Molecular and Cellular Biology, 30 (18). pp. 4379-4390. ISSN 0270-7306 (doi:10.1128/MCB.01193-09)

2009

Li, X. et al. (2009) A scanning peptide array approach uncovers association sites within the JNK/βarrestin signalling complex. Febs Letters, 583 (20). pp. 3310-3316. ISSN 0014-5793 (doi:10.1016/j.febslet.2009.09.035)

Kiely, P.A., Baillie, G.S., Barrett, R., Buckley, D.A., Adams, D.R., Houslay, M.D., and O'Connor, R. (2009) Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for IGF-I-mediated regulation of focal adhesion kinase (FAK). Journal of Biological Chemistry, 284 . pp. 20263-20274. ISSN 0021-9258 (doi:10.1074/jbc.M109.017640)

Baillie, G.S. (2009) Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS Journal, 276 (7). pp. 1790-1799. ISSN 1742-464X (doi:10.1111/j.1742-4658.2009.06926.x)

Kiely, P.A., Baillie, G.S., Barrett, R., Buckley, D.A., Adams, D.R., Houslay, M.D., and O'Connor, R. (2009) Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor i-mediated regulation of focal adhesion kinase. Journal of Biological Chemistry, 284 (30). pp. 20263-20274. ISSN 0021-9258 (doi:10.1074/jbc.M109.017640)

Li, X., Baillie, G.S., and Houslay, M.D. (2009) Mdm2 directs the ubiquitination of {Beta}-arrestin-sequestered cAMP phosphodiesterase-4D5. Journal of Biological Chemistry, 284 (24). pp. 16170-16182. ISSN 0021-9258 (doi:10.1074/jbc.M109.008078)

Ong, W.K., Gribble, F.M., Reimann, F., Lynch, M.J., Houslay, M.D., Baillie, G.S., Furman, B.L., and Pyne, N.J. (2009) The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. British Journal of Pharmacology, 157 (4). pp. 633-644. ISSN 0007-1188 (doi:10.1111/j.1476-5381.2009.00194.x)

Terrenoire, C., Houslay, M.D., Baillie, G.S., and Kass, R.S. (2009) The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3. Journal of Biological Chemistry, 284 (14). pp. 9140-9146. ISSN 0021-9258 (doi:10.1074/jbc.M805366200)

Vecsey, C.G. et al. (2009) Sleep deprivation impairs cAMP signalling in the hippocampus. Nature, 461 (7267). pp. 1122-1125. ISSN 0028-0836 (doi:10.1038/nature08488)

2008

Collins, D.M., Murdoch, H., Dunlop, A.J., Charych, E., Baillie, G.S., Wang, Q., Herberg, F.W., Brandon, N., Prinz, A., and Houslay, M.D. (2008) Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cellular Signalling, 20 (12). pp. 2356-2369. ISSN 0898-6568 (doi:10.1016/j.cellsig.2008.09.017)

Kiely, P.A., Baillie, G.S., Lynch, M.J., Houslay, M.D., and O'Connor, R. (2008) Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and {beta}1 integrin and for tumor cell proliferation and migration. Journal of Biological Chemistry, 283 (34). pp. 22952-22961. ISSN 0021-9258 (doi:10.1074/jbc.M800802200)

Di Benedetto, G., Zoccarato, A., Lissandron, V., Terrin, A., Li, X., Houslay, M.D., Baillie, G.S., and Zaccolo, M. (2008) Protein kinase A type I and type II define distinct intracellular signaling compartments. Circulation Research, 103 (8). pp. 836-844. ISSN 0009-7330 (doi:10.1161/CIRCRESAHA.108.174813)

Huston, E., Lynch, M.J., Mohamed, A., Collins, D.M., Hill, E.V., McLeod, R., Krause, E., Baillie, G.S., and Houslay, M.D. (2008) EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 105 (35). pp. 12791-12796. ISSN 0027-8424 (doi:10.1073/pnas.0805167105)

Mackenzie, Kirsty F. et al. (2008) Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochemical Journal, 411 (2). pp. 361-369. ISSN 0264-6021 (doi:10.1042/BJ20071251)

McCahill, A., Campbell, L., McSorley, T., Lynch, M.J., Li, X., Yan, C., Baillie, G.S., and Houslay, M.D. (2008) In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). Cellular Signalling, 20 (11). pp. 2071-2083. ISSN 08986568 (doi:10.1016/j.cellsig.2008.07.017)

Meng, D., Lynch, M. J., Huston, E., Beyermann, M., Eichhorst, J., Adams, D. R., Klusmann, E., Houslay, M.D., and Baillie, G.S. (2008) MEK1 Binds Directly to  Arrestin1, Influencing Both Its Phosphorylation by ERK and the Timing of Its Isoprenaline-stimulated Internalization. Journal of Biological Chemistry, 284 (17). pp. 11425-11435. ISSN 0021-9258 (doi:10.1074/jbc.M806395200)

Xu, T., Baillie, G.S., Bhari, N., Houslay, T.M., Pitt, A.M., Adams, D.R., Kolch, W., Houslay, M.D., and Milligan, G. (2008) Mutations of β-arrestin 2 that limit self-association also interfere with interactions with the β2-adrenoceptor and the ERK1/2 MAPKs: implications for β2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochemical Journal, 413 . pp. 51-60. ISSN 0264-6021 (doi:10.1042/BJ20080685)

2007

Sachs, B.D. et al. (2007) p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. Journal of Cell Biology, 177 (6). pp. 1119-1132. ISSN 1540-8140 (doi:10.1083%2Fjcb.200701040)

Baillie, G.S. et al. (2007) Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays. Biochemical Journal, 404 (1). pp. 71-80. ISSN 0264-6021 (doi:10.1042%2FBJ20070005)

Cheung, YF, Kan, ZY, Garrett-Engele, P, Gall, I, Murdoch, H, Baillie, GS, Camargo, LM, Johnson, JM, Houslay, MD, and Castle, JC (2007) PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). Journal of Pharmacology and Experimental Therapeutics, 322 . pp. 600-609. (doi:10.1124/jpet.107.122218)

Houslay, MD, Baillie, GS, and Maurice, DH (2007) cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system - A molecular toolbox for generating compartmentalized cAMP signaling. Circulation Research, 100 . pp. 950-966. (doi:10.1161/01.RES.0000261934.56938.38)

McEwan, DG, Brunton, VG, Baillie, GS, Leslie, NR, Houslay, MD, and Frame, MC (2007) Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Research, 67 . pp. 5248-5257. (doi:10.1158/0008-5472.CAN-07-0097)

Smith, KJ et al. (2007) H-1 NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, arrestin and RACK1. Cellular Signalling, 19 . pp. 2612-2624. (doi:10.1016/j.cellsig.2007.08.015)

Stefan, E et al. (2007) Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. Journal of the American Society of Nephrology, 18 . pp. 199-212. (doi:10.1681/ASN.2006020132)

Willoughby, D, Baillie, GS, Lynch, MJ, Ciruela, A, Houslay, MD, and Cooper, DMF (2007) Dynamic regulation, desensitization, and cross-talk in discrete subcellular microdomains during beta(2)-adrenoceptor and prostanoid receptor cAMP signaling. Journal of Biological Chemistry, 282 . pp. 34235-34249. ISSN 0021-9258 (doi:10.1074/jbc.M706765200)

2006

Bolger, G.B. et al. (2006) Scanning peptide array analysis identify overlapping binding sites for the signaling scaffold proteins, beta-arestin and RACK1 in the cAMP-specific phosphodiesterase, PDE4D5. Biochemical Journal, 398 (1). pp. 23-36. ISSN 0264-6021 (doi:10.1042/BJ20060423)

Bolger, GB et al. (2006) Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochemical Journal, 398 . pp. 23-36. ISSN 0264-6021 (doi:10.1042/BJ20060423)

Gronning, LM, Baillie, GS, Cederberg, A, Lynch, MJ, Houslay, MD, Enerback, S, and Tasken, K (2006) Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice. Febs Letters, 580 . pp. 4126-4130. (doi:10.1016/j.febslet.2006.06.058)

Hayavi, S, Baillie, G, Owens, MD, and Halbert, GW (2006) Receptor dependent cellular uptake of synthetic low density lipoprotein by mammalian cells in serum-free tissue culture. Journal of Pharmacy and Pharmacology, 58 . pp. 1337-1342. (doi:10.1211/jpp.58.10.0006)

Houslay, MD, and Baillie, GS (2006) Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation. Biochemical Society Transactions, 34 . pp. 474-475.

Huston, E, Houslay, TM, Baillie, GS, and Houslay, MD (2006) cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochemical Society Transactions, 34 . pp. 504-509.

Li, X, Huston, E, Lynch, MJ, Houslay, MD, and Baillie, GS (2006) Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293 beta 2 cells and cardiac myocytes. Biochemical Journal, 394 . pp. 427-435. ISSN 0264-6021 (doi:10.1042/BJ20051560)

McSorley, T, Stefan, E, Henn, V, Wiesner, B, Baillie, GS, Houslay, MD, Rosenthal, W, and Klussmann, E (2006) Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. European Journal of Cell Biology, 85 . pp. 673-678. (doi:10.1016/j.ejcb.2006.01.005)

Terrin, A et al. (2006) PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. Journal of Cell Biology, 175 . pp. 441-451. (doi:10.1083/jcb.200605050)

2005

Baillie, GS, and Houslay, MD (2005) Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Current Opinion in Cell Biology, 17 . pp. 129-134. (doi:10.1016/j.ceb.2005.01.003)

Baillie, GS, Scott, JD, and Houslay, MD (2005) Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. Febs Letters, 579 . pp. 3264-3270. (doi:10.1016/j.febslet.2005.03.089)

Henn, V, Stefan, E, Baillie, GS, Houslay, MD, Rosenthal, W, and Klussmann, E (2005) Compartmentalized cAMP signalling regulates vasopressin-mediated water reabsorption by controlling aquaporin-2. Biochemical Society Transactions, 33 . pp. 1316-1318.

Hill, E.V., Houslay, M.D., and Baillie, G.S. (2005) Investigation of extracellular signal-regulated kinase 2 mitogen-activated protein kinase phosphorylation and regulation of activity of PDE4 cyclic adenosine monophosphate-specific phosphodiesterases. Methods in Molecular Biology, 307 . pp. 225-238. ISSN 1064-3745 (doi:10.1385/1-59259-839-0:225)

Houslay, MD, and Baillie, GS (2005) beta-Arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta(2)-adrenoceptor signalling to activation of ERK. Biochemical Society Transactions, 33 . pp. 1333-1336.

Lynch, MJ, Baillie, GS, Mohamed, A, Li, X, Maisonneuve, C, Klussmann, E, van Heeke, G, and Houslay, MD (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta(2)-adrenergic receptor to activation of ERK in HEK293B2 cells. Journal of Biological Chemistry, 280 . pp. 33178-33189. ISSN 0021-9258 (doi:10.1074/jbc.M414316200)

Millar, JK et al. (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science, 310 . pp. 1187-1191. ISSN 0036-8075 (doi:10.1126/science.1112915)

2004

Abrahamsen, H, Baillie, G, Ngai, J, Vang, T, Nika, K, Ruppelt, A, Mustelin, T, Zaccolo, M, Houslay, M, and Tasken, K (2004) TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. Journal of Immunology, 173 . pp. 4847-4858.

Barber, R., Baillie, G.S., Bergmann, R., Shepherd, M.C., Sepper, R., Houslay, M.D., and Van Heeke, G. (2004) Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. American Journal of Physiology: Lung Cellular and Molecular Physiology, 287 . L332-L343. (doi:10.1152/ajplung.00384.2003)

Johnston, LA et al. (2004) Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochemical Journal, 380 . pp. 371-384. ISSN 0264-6021

Shepherd, MC, Baillie, GS, Stirling, DI, and Houslay, MD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. British Journal of Pharmacology, 142 . pp. 339-351. ISSN 0007-1188 (doi:10.1038/sj.bjp.0705770)

2003

Baillie, GS, Sood, A, McPhee, I, Gall, I, Perry, SJ, Lefkowitz, RJ, and Houslay, MD (2003) beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from G(s) to G(i). Proceedings of the National Academy of Sciences of the United States of America, 100 . pp. 940-945. (doi:10.1073/pnas.262787199)

Bolger, GB, McCahill, A, Huston, E, Cheung, YF, McSorley, T, Baillie, GS, and Houslay, MD (2003) The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. Journal of Biological Chemistry, 278 . pp. 49230-49238. ISSN 0021-9258 (doi:10.1074/jbc.M303772200)

Bolger, GB, Peden, AH, Steele, MR, MacKenzie, C, McEwan, DG, Wallace, DA, Huston, E, Baillie, GS, and Houslay, MD (2003) Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. Journal of Biological Chemistry, 278 . pp. 33351-33363. ISSN 0021-9258 (doi:10.1074/jbc.M303269200)

Houslay, MD, and Baillie, GS (2003) The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. Biochemical Society Transactions, 31 . pp. 1186-1190.

Shepherd, M, McSorley, T, Olsen, AE, Johnston, LA, Thomson, NC, Baillie, GS, Houslay, MD, and Bolger, GB (2003) Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochemical Journal, 370 . pp. 429-438. ISSN 0264-6021

Terry, R, Cheung, YF, Praestegaard, M, Baillie, GS, Huston, E, Gall, I, Adams, DR, and Houslay, MD (2003) Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cellular Signalling, 15 . pp. 955-971. (doi:10.1016/S0898-6568(03)00092-5)

2002

Adam, B, Baillie, GS, and Douglas, LJ (2002) Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. Journal of Medical Microbiology, 51 . pp. 344-349.

Baillie, G (2002) A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. Journal of Lipid Research, 43 (1). pp. 69-73.

Baillie, GS et al. (2002) TAPAS-1, a novel microdomaln within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. Journal of Biological Chemistry, 277 . pp. 28298-28309. ISSN 0021-9258 (doi:10.1074/jbc.M108353200)

MacKenzie, SJ, Baillie, GS, McPhee, I, MacKenzie, C, Seamons, R, McSorley, T, Millen, J, Beard, MB, van Heeke, G, and Houslay, MD (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). British Journal of Pharmacology, 136 . pp. 421-433.

Perry, SJ et al. (2002) Targeting of cyclic AMP degradation to beta(2)-adrenergic receptors by beta-arrestins. Science, 298 . pp. 834-836.

2001

Baillie, G (2001) Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences. International Journal of Pharmaceutics, 228 (39479). pp. 109-117. (doi:10.1016/S0378-5173(01)00818-3)

Baillie, G, MacKenzie, SJ, and Houslay, MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Molecular Pharmacology, 60 . pp. 1100-1111.

This list was generated on Thu May 2 21:23:15 2013 BST.

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Extracellular signal-regulated kinase 5 (ERK5) and regulation of neuroendocrine differentiation in prostate cancer
    Scottish Executive Health Department
    2012 - 2014
     
  • cAMP phosphodiesterase-4: signalling complexes, regulation and potential therapeutic targets.
    Medical Research Council
    2012 - 2015
     
  • Small molecules that induce the cardio-protective effects of HSP20
    Heart Research UK
    2012 - 2014
     
  • Disrupting arresting binding partners to influence cell shape and mobility
    Royal Society
    2011 - 2013
     
  • Phosphodiesterase-4 isoforms - intracellular targeting, regulation and potential therapeutic targets
    MRC
    2007 - 2012
     
  • Transatlantic networks of excellence in cardiovascular disease
    Fondation Leducq
    2006 - 2012
     

Editorial Board

  • 2007 - ongoing: Journal of Cellular Signalling - Co-editor

Invited International Presentations

  • 2011: Charles Darwin House, London, UK - EPS sponsored meeting "Peptide arrays as tools for studying protein interactions"
  • 2010: Waterville Valley, New Hampshire, USA - Gordon Research Conference, Cyclic Nucleotide Phosphodiesterases
  • 2010: Breckenridge, Colorado, USA - Keystone Symposia on Molecular and Cellular Biology, G Protein Coupled Receptors
  • 2010: Paris, France - EU Gene Heart Seminar Series
  • 2010: Oslo, Norway - 3rd international meeting on Anchored cAMP Signalling
  • 2008: Oslo, Norway - FEBS/ESF Workshop, 16th Protein Kinase Meeting
  • 2008: Barga, Italy - Gordon Research Conference on Cyclic Nucleotide Phosphodiesterases
  • 2006: Cambridge, England, UK - Invited speaker at Biochemical Society Focused Meeting on Compartmentalisation of cAMP Signaling, 2006, King's College, Cambridge
  • 2006: University of Durham, England, UK - Contemporary Issues in Cyclic Nucleotide Signalling
  • 2006: University of New England, USA - Gordon Research conference on Cyclic Nucleotide Phosphodiesterases
  • 2005: Berlin-Buch - 1st International Meeting on Anchored cAMP Signalling Pathways
  • 2004: Mainz, Germany - "New trends in G protein-mediated signalling", 45th Annual Meeting, German Society for Experimental and Clinical Pharmacology
  • 2003: University of Essex, Essex, UK - Biochemical Society Meeting 679, Stress